X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AI-09 (botulinum toxin) employs a proprietary technology that allows an injectable botulinum to be formulated as a convenient, ready-to-use liquid product, instead of requiring reconstitution with saline prior to use.
Lead Product(s): Botulinum Toxin
Therapeutic Area: Dermatology Product Name: AI-09
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
As part of the agreement, HTL will validate and operate botulinum manufacturing facility in US. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and primary axillary hyperhidrosis.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: ET-01
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: HTL Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 08, 2021
Details:
One license is for Eirion's neuromodulator-based product candidates, ET-01 and AI-09 for aesthetic indications; and a second license is for Eirion's small molecule product candidates, ET-02 and ET-03, which are intended for the treatment of hair loss and hair greying.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: ET-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Haohai Biological Technology
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
